<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052515</url>
  </required_header>
  <id_info>
    <org_study_id>436/14-06-21</org_study_id>
    <nct_id>NCT05052515</nct_id>
  </id_info>
  <brief_title>The Effects of Natural Extracts Supplementation on NASH Patients</brief_title>
  <official_title>The Effects of Choline,Vitamin C, Vitamin E and Ampelopsis Grossedentata Natural Extracts Supplementation on NASH Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laikο General Hospital, Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global wave of obesity has affected dramatically the incidence of non-alcoholic fatty&#xD;
      liver disease (NAFLD) making it the leading cause of liver disease in the western world.&#xD;
      NAFLD is considered the hepatic manifestation of metabolic syndrome and is strongly&#xD;
      associated with type II diabetes, sleep apnea and cardiovascular disease. Although&#xD;
      cardiovascular disease is the leading cause of death in patients with NAFLD, a subset of&#xD;
      patients who meet the histological criteria for steatohepatitis have the highest risk for&#xD;
      liver-related morbidity and mortality.&#xD;
&#xD;
      Reviewing literature, it appears that several pathophysiologic mechanisms related to&#xD;
      metabolism, inflammation and fibrosis are deregulated in NAFLD. Choline, Vitamin C, Vitamin E&#xD;
      and Ampelopsis Grossedentata natural extracts exhibit high antioxidant activity. In contrast&#xD;
      to Vitamin E, which has been extensively studied and has a role as a drug of choice in&#xD;
      non-diabetic patients with NAFLD, epidemiological or clinical data for the use of Choline,&#xD;
      Vitamin C, Ampelopsis Grossedentata natural extracts or their combination in NAFLD are&#xD;
      limited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be randomized, placebo-controlled and double-blinded in order to avoid a&#xD;
      number of systemic errors, such as selection bias and the placebo effect. Patients will be&#xD;
      randomly assigned to one of the two categories: (A) a placebo group (B) a Choline - Vitamin&#xD;
      C, E and Ampelopsis Grossedentata natural extracts tablets supplementation group (two tablets&#xD;
      twice per day). The duration of the intervention will be 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint</measure>
    <time_frame>It will be estimated at 12 months.</time_frame>
    <description>The primary endpoint will be the clinically beneficial reduction in ALT, defined as the return of ALT within normal limits or the reduction of ALT by&gt; 50% of its baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of ALT and γGT</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Liver stiffness</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement of liver stiffness at liver elastography by &gt; 1 kPa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of FIB-4 score</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of NAFLD Fibrosis score</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment Two tablets twice a day for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutritional Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment Two tablets twice a day for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts</intervention_name>
    <description>Patients with NAFLD will be randomly allocated to receive Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts supplementation</description>
    <arm_group_label>Nutritional Supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients with NAFLD will be randomly allocated to receive placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &gt;1.5 times the greater normal value with or without&#xD;
             elevated γ-glutamyl transpeptidase (γGT)&#xD;
&#xD;
          -  Hepatic steatosis-indicating findings on ultrasound and / or liver biopsy&#xD;
&#xD;
          -  BMI 20-40 Kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol consumption &gt; 210 or &gt; 140 grams per week for men or women, respectively&#xD;
&#xD;
          -  Use of a potentially hepatotoxic drug&#xD;
&#xD;
          -  Detection of hepatitis B virus (HBsAg) surface antigen or Hepatitis C virus antibodies&#xD;
             (anti-HCV) or HIV antibodies&#xD;
&#xD;
          -  The coexistence of α systemic disease with potentially hepatic involvement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgios Papatheodoridis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgios Papatheodoridis, MD PhD</last_name>
    <phone>+30 213 206 1115</phone>
    <email>gepapath@med.uoa.gr</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Georgios Papatheodoridis</investigator_full_name>
    <investigator_title>Professor in Medicine &amp; Gastroenterology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

